Company Description
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
The company’s product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
The company markets its products through direct sales organization, as well as through distributors in the United States and internationally.
Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
| Country | United States |
| Founded | 1998 |
| IPO Date | Jun 25, 2015 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 907 |
| CEO | Thomas Burns |
Contact Details
Address: One Glaukos Way Aliso Viejo, California 92656 United States | |
| Phone | 949 367 9600 |
| Website | glaukos.com |
Stock Details
| Ticker Symbol | GKOS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001192448 |
| CUSIP Number | 377322102 |
| ISIN Number | US3773221029 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Thomas Burns | Chief Executive Officer |
| Alex Thurman | Chief Financial Officer |
| Joseph Gilliam | Chief Operating Officer |
| Christopher Lewis | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 144 | Filing |
| Dec 20, 2024 | 144 | Filing |
| Dec 11, 2024 | 144 | Filing |
| Dec 9, 2024 | 8-K | Current Report |
| Dec 3, 2024 | 8-K | Current Report |
| Nov 15, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 5, 2024 | 10-Q | Quarterly Report |
| Nov 4, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 144 | Filing |